Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zypol
- Development stage
- Unknown
- Lead developer
- Unimed Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zypol is a pharmaceutical product containing 500 mg of paracetamol (acetaminophen), a small molecule analgesic and antipyretic. Developed and manufactured by Unimed Healthcare, a South African generic pharmaceutical company, Zypol is indicated for the treatment of mild to moderate pain and inflammation, as well as symptoms associated with the common cold and influenza. It functions primarily by inhibiting prostaglandin synthesis within the central nervous system, which elevates the pain threshold and reduces fever. The medication is available as an over-the-counter (OTC) oral tablet, characterized as a flat, round, green tablet with a break line.
- Brand names
- Zypol
Beyond the preview
Go deeper on Zypol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zypol.